Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Morning Review
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
    • Insider Transactions
    • Transkriptioner
  • InderesTV
  • Portfölj
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • Om oss
    • Bolag under bevakning
    • Teamet
Regulatoriskt pressmeddelande

BioGaia's results for the fourth quarter to exceed market expectations

BioGaia
Ladda ner börsmeddelandet

(Figures in the brackets refer to the same period the previous year)

During the fourth quarter of 2025, BioGaia's sales were positively affected by quarterly variations for individual orders of approximately SEK 35 million.

For the fourth quarter, sales are preliminarily estimated at SEK 441 million (365), an increase of 21% (excluding foreign exchange effects, 32%). The operating profit for the fourth quarter is preliminarily estimated at SEK 121 million (103), an increase of 17% and an operating margin of 27% (28%).

BioGaia publishes the interim report for the fourth quarter 2025 on Thursday, February 12, 2026, at 08:00 a.m. CET, followed by an audiocast at 09:30 a.m. CET.

Follow us:
Subscribe to BioGaia press releases here
LinkedIn here

Contacts:
Alexander Kotsinas, CFO
Email: 
alexander.kotsinas@biogaia.com
Phone: +46 735 00 11 11

Mikaela Idermark Stern, Corporate Communications
Email: 
mikaela.idermark.stern@biogaia.com
Phone: +46 730 95 61 50

About BioGaia
BioGaia is a Swedish probiotic company that has been at the forefront of microbiome research for more than 35 years. BioGaia develops, manufactures, markets, and sells probiotic products focused on gut health, immune health, and oral health. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaiagroup.com

This disclosure contains information that BioGaia is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person set out above, at 08:00 a.m. CET on February 3, 2026.

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Ta kontakt
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.